Praxis Precision Medicines 

Yahoo Finance • 5 days ago

Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting

BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into therapies for central nervous system (CNS) disorders driven by neuron... Full story

Yahoo Finance • 9 days ago

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story

Yahoo Finance • 10 days ago

Praxis a new buy at BTIG as biotech is a top pick for 2026

[Wall Street New York stock exchange stock market] alexsl * BTIG has initiated Praxis Precision Medicines (PRAX [https://seekingalpha.com/symbol/PRAX]) with a buy rating saying that the central nervous system-focused biotech is a top pi... Full story

Yahoo Finance • 24 days ago

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story

Yahoo Finance • 24 days ago

Praxis Precision Medicines GAAP EPS of -$3.36 beats by $0.11

* Praxis Precision Medicines press release [https://seekingalpha.com/pr/20294228-praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2025-financial] (PRAX [https://seekingalpha.com/symbol/PRAX]): Q3 GAAP EPS of... Full story

Yahoo Finance • last month

Meet the Biotech Stock That Just Jumped 251% Higher

Key Points Shares of Praxis Precision Medicine shot 251% higher in a little over a week during the month of October. Praxis Precision Medicine announced successful results from a phase 3 trial with its lead candidate. There are three lat... Full story

Yahoo Finance • last month

Tesla, Nvidia, Rigetti, Praxis: Trending Stocks

Tesla (TSLA) continued its slide in the pre-market on another bearish analyst report, and mounting questions around Elon Musk company's ability to deliver on robotics and AI promises. Nvidia (NVDA) shares swing down then recover some groun... Full story

Yahoo Finance • last month

Trending tickers: Praxis, Western Alliance, Rigetti, Micron and Smiths

Praxis Precision (PRAX) Praxis Precision Medicines was the number one trending ticker on Yahoo Finance this Friday morning, after the clinical-stage biopharmaceutical company unveiled plans to raise $525m (£390m) through a public share of... Full story

Yahoo Finance • last month

Praxis Precision Medicines prices $525M public offering

* Praxis Precision Medicines (NASDAQ:PRAX [https://seekingalpha.com/symbol/PRAX]) has priced [https://seekingalpha.com/pr/20269948-praxis-precision-medicines-inc-announces-pricing-of-525-million-public-offering] a public offering to rais... Full story

Yahoo Finance • last month

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story

Yahoo Finance • last month

Praxis Precision Medicines announces proposed public offering

* Praxis Precision Medicines (NASDAQ:PRAX [https://seekingalpha.com/symbol/PRAX]) said on Thursday it plans to offer shares of its common stock and prefunded warrants in a public offering, with all securities to be sold by the company.... Full story

Yahoo Finance • last month

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story

Yahoo Finance • last month

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks fell late Thursday afternoon with the NYSE Health Care Index down 0.2% and the He PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Sector Update: Health Care Stocks Advance Thursday Afternoon

Health care stocks rose Thursday afternoon, with the NYSE Health Care Index adding 0.3% and the Heal PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Praxis surges after late-stage trial success for movement disorder therapy

[$100 Growth Rolling Banknote, Green Arrow, Object + Shadow Clipping Path] Praxis Precision Medicines (NASDAQ:PRAX [https://seekingalpha.com/symbol/PRAX]) continued to climb on Thursday, adding more than 200% in the afternoon session as W... Full story

Yahoo Finance • last month

Stocks Climb as Strong AI Spending Boosts Market Confidence

The S&P 500 Index ($SPX) (SPY) today is up +0.24%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.16%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.50%.  December E-mini S&P futures (ESZ25) are up +0.27%, and December E-mini Nas... Full story

Yahoo Finance • 2 months ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story

Yahoo Finance • 2 months ago

PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Praxis (PRAX) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Praxis and would like to discus... Full story

Yahoo Finance • 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) (NASDAQ: PRAX).  Such investors are advised to contact Danielle Pe... Full story

Yahoo Finance • 3 months ago

Praxis Precision Medicines to Participate in September Investor Conferences

BOSTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS)... Full story